Goldman Sachs asks in biotech research report: 'Is curing patients a sustainable business model?'

Found on CNBC on Sunday, 15 April 2018
Browse Science

"The potential to deliver 'one shot cures' is one of the most attractive aspects of gene therapy, genetically-engineered cell therapy and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies," analyst Salveen Richter wrote in the note to clients Tuesday. "While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow."

"GILD is a case in point, where the success of its hepatitis C franchise has gradually exhausted the available pool of treatable patients," the analyst wrote.

That makes you wonder if that "analyst" would think the same way if one of these "one shot cures" could end a disease which would make Salveen Jaswal Richter's life horrible. Maybe karma will teach her a harsh lesson.